Dr. Robert Ang is the CEO of Vor Biopharma, a clinical-stage cell and genome engineering therapy company. In this episode, Dr. Ang discusses the challenges of treating cancer, particularly acute myeloid leukemia (AML), and the need for new and innovative approaches. The conversation delves into the challenges of navigating clinical trials during the pandemic and securing funding for research and development. Lastly, he explains how Vor Biopharma is using cell and gene therapies, such as CAR-T cells and genome engineering, to target AML and potentially cure patients. Host: John Joson NgEditors: Jessie Wong, John Joson NgThe show notes and transcripts for the episode can be found onnucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via [email protected]. 01:15 - Introduction07:47 - Cancer and treatment modalities12:02 - Vor’s approach to treating AML31:55 - Investing in clinical manufacturing34:21 - Navigating clinical trials and funding during the pandemic39:53 - Looking ahead